KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBT: 2014-2025

Historic EBT for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Sep 2025 value amounting to $32.0 million.

  • Aurinia Pharmaceuticals' EBT rose 115.86% to $32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.6 million, marking a year-over-year increase of 495.41%. This contributed to the annual value of $7.4 million for FY2024, which is 109.61% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' EBT stood at $32.0 million, which was up 44.26% from $22.2 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year EBT high stood at $32.0 million for Q3 2025, and its period low was -$50.4 million during Q1 2021.
  • For the 3-year period, Aurinia Pharmaceuticals' EBT averaged around $767,818, with its median value being $1.2 million (2024).
  • In the last 5 years, Aurinia Pharmaceuticals' EBT slumped by 311.72% in 2021 and then soared by 1,399.05% in 2025.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' EBT stood at -$32.6 million in 2021, then increased by 22.72% to -$25.2 million in 2022, then decreased by 4.86% to -$26.4 million in 2023, then surged by 104.44% to $1.2 million in 2024, then surged by 115.86% to $32.0 million in 2025.
  • Its EBT stands at $32.0 million for Q3 2025, versus $22.2 million for Q2 2025 and $24.3 million for Q1 2025.